Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;22(1):25-44.
doi: 10.1038/s41568-021-00413-6. Epub 2021 Oct 20.

Overcoming TGFβ-mediated immune evasion in cancer

Daniele V F Tauriello  1 , Elena Sancho  2   3 , Eduard Batlle  4   5   6
Affiliations
Free article
Review

Overcoming TGFβ-mediated immune evasion in cancer

Daniele V F Tauriello et al. Nat Rev Cancer. 2022 Jan.
Free article

Abstract

Transforming growth factor-β (TGFβ) signalling controls multiple cell fate decisions during development and tissue homeostasis; hence, dysregulation of this pathway can drive several diseases, including cancer. Here we discuss the influence that TGFβ exerts on the composition and behaviour of different cell populations present in the tumour immune microenvironment, and the context-dependent functions of this cytokine in suppressing or promoting cancer. During homeostasis, TGFβ controls inflammatory responses triggered by exposure to the outside milieu in barrier tissues. Lack of TGFβ exacerbates inflammation, leading to tissue damage and cellular transformation. In contrast, as tumours progress, they leverage TGFβ to drive an unrestrained wound-healing programme in cancer-associated fibroblasts, as well as to suppress the adaptive immune system and the innate immune system. In consonance with this key role in reprogramming the tumour microenvironment, emerging data demonstrate that TGFβ-inhibitory therapies can restore cancer immunity. Indeed, this approach can synergize with other immunotherapies - including immune checkpoint blockade - to unleash robust antitumour immune responses in preclinical cancer models. Despite initial challenges in clinical translation, these findings have sparked the development of multiple therapeutic strategies that inhibit the TGFβ pathway, many of which are currently in clinical evaluation.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Batlle, E. & Massagué, J. Transforming growth factor-β signaling in immunity and cancer. Immunity 50, 924–940 (2019). - PubMed - PMC - DOI
    1. David, C. J. & Massagué, J. Contextual determinants of TGFβ action in development, immunity and cancer. Nat. Rev. Mol. Cell Biol. 19, 419–435 (2018). This comprehensive review summarizes current knowledge of the TGFβ signalling transduction pathway and discusses the molecular basis for contextual TGFβ responses in different cell types. - PubMed - PMC - DOI
    1. Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 2018 202 20, 69–84 (2018). - DOI
    1. Katsuno, Y. & Derynck, R. Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-β family. Dev. Cell 56, 726–746 (2021). - PubMed - DOI
    1. Moses, H. L., Roberts, A. B. & Derynck, R. The discovery and early days of TGF-β: a historical perspective. Cold Spring Harb. Perspect. Biol. 8, a021865 (2016). - PubMed - PMC - DOI

Publication types

Substances